Sugi Predict

Sugi Predict / Compounds / SCHEMBL445249

SCHEMBL445249

SCHEMBL445249

CC(C)(C)OC(=O)Nc1ccon1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.49
▸ POLB P06746 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ ATM Q13315 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ GAA P10253 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17443443 0.84 ATM (0.46) RAB9APOLBALDH1A1L3MBTL1ATM
SCHEMBL3089402 0.82 ATM (0.50) RAB9APOLBALDH1A1L3MBTL1ATM
SCHEMBL31753001 0.82 SMN1; SMN2 (0.58) RAB9AALDH1A1SMN1; SMN2KDM4EKMT2A
SCHEMBL13014025 0.77 RAB9A (0.53) RAB9APOLBALDH1A1L3MBTL1ATM
SCHEMBL7762845 0.75 RAB9A (0.58) RAB9APOLBALDH1A1L3MBTL1ATM
SCHEMBL171892 0.74 — —
SCHEMBL28457139 0.74 PTPN2 (0.62) RAB9ANPC1KMT2AHPGD
SCHEMBL29394473 0.74 LCK (0.47) RAB9APOLBNPC1SMN1; SMN2GAA
SCHEMBL2174857 0.73 MAPT (0.56) RAB9APOLBALDH1A1L3MBTL1NPC1
SCHEMBL13002465 0.73 GAPDH (0.52) RAB9APOLBALDH1A1L3MBTL1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109369553-B Method for synthesizing N-3-isoxazole carbamic acid tert-butyl ester 上海凌凯医药科技有限公司 2023-04-11 — — CN claimed
CN-109369553-A A method of efficiently synthesizing N-3- isoxazole t-butyl carbamate 上海凌凯医药科技有限公司 2019-02-22 — — CN claimed
US-20100286211-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2010-11-11 — — US claimed
US-20100204477-A1 Methods and Processes For Syntheses and Manufacture of Antimicrobial 1(Ortho-Fluorophenyl)dihydropyridones MICURX PHARMACEUTICALS, INC. (KY) 2010-08-12 — — US claimed
WO-2010091272-A1 METHODS AND PROCESSES FOR SYNTHESES AND MANUFACTURE OF ANTIMICROBIAL 1-(ORTHO-FLUOROPHENYL)DIHYDROPYRIDONES MICURX PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO claimed
EP-1799677-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS Ranbaxy Laboratories Limited (IN) 2007-06-27 — — EP claimed
WO-2006038100-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2006-04-13 — — WO claimed
US-12109203-B2 Substituted oxazolidinones for the treatment of mammalian infections ZYDUS LIFESCIENCES LIMITED (IN) 2024-10-08 — — US disclosed
CN-113603683-B Substituted phenyl oxazolidinones for antimicrobial treatment 结核病药物开发全球联盟公司 2024-06-14 — — CN disclosed
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2024-04-23 — — US disclosed
WO-2024069378-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF MAMMALIAN INFECTIONS ZYDUS LIFESCIENCES LIMITED (IN) 2024-04-04 — — WO disclosed
CN-112368289-B C26-linked rapamycin analogues as MTOR inhibitors 锐新医药公司 2024-02-20 — — CN disclosed
CN-112262142-B Benzenesulfonamide compounds and their use as therapeutic agents 泽农医药公司 2023-11-14 — — CN disclosed
EP-1242416-A1 SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 2002-09-25 — — EP disclosed
US-20020115669-A1 Oxazolidinone chemotherapeutic agents ABBOTT LABORATORIES 2002-08-22 — — US disclosed
WO-2002018354-A1 OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS ABBOTT LABORATORIES (US) 2002-03-07 — — WO disclosed
CN-1322203-A Heterocyclic aminomethyl oxazolidinones as antibacterial agents ASTRA ZENECA N V (SE) 2001-11-14 — — CN disclosed
EP-1121358-A1 HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS AstraZeneca AB (SE) 2001-08-08 — — EP disclosed
WO-2001040222-A1 SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2001-06-07 — — WO disclosed
WO-2000021960-A1 HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THPO, TBCD, OXA1L RAB9A 2986/4885POLB 410/4885ALDH1A1 1310/4885
US-20100286211-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS OXA1L, PDK4, MLYCD RAB9A 4328/4885POLB 529/4885ALDH1A1 944/4885
US-12109203-B2 Substituted oxazolidinones for the treatment of mammalian infections OXA1L, IL4I1, PEPD RAB9A 2859/4885POLB 773/4885ALDH1A1 797/4885
US-20100204477-A1 Methods and Processes For Syntheses and Manufacture of Antimicrobial 1(Ortho-Fluorophenyl)dihydropyridones DHPS, FDPS, CYP2F1 RAB9A 780/4885POLB 1320/4885ALDH1A1 232/4885
US-20020115669-A1 Oxazolidinone chemotherapeutic agents TOP1, OXA1L, TK1 RAB9A 3586/4885POLB 111/4885ALDH1A1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.